Master Rollover Protocol for Continued Safety Assessment of Study Drug

Lilly

Status

Conditions: Cancer

Treatments: Drug: LY2503029; Drug: LY3847429; Drug: LY3838915; Drug: LY3023414

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT02632994

I8I-MC-JYAA (Other Identifier)

16161

Details and patient eligibility

About

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion criteria

• Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.